RxDoctor Payments DataLook up a doctor →

Richard Herrscher, MD

Allergy & Immunology · Plano, TXNPI 1568425700

Payments from drug & device makers

$44,318in general payments, 2019–2025

Across 414 payments — averaging $107.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ADMA Biomanufacturing LLC$35K
  • Blueprint Medicines Corporation$2K
  • AstraZeneca$1K
  • GSK$829
  • Amgen$520
  • Novartis$501
  • plus $5K from 37 others
$13,068in research payments, 2019–2025

Across 16 payments — averaging $816.75 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • ADMA Biomanufacturing LLC$13K

What the payments were for

  • Consulting fees$2661%
  • Speaking & faculty fees$7,04834%
  • Travel & lodging$3,90019%
  • Food & beverage$8,93844%
  • Education$3061%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$44,318 in reported general payments places this provider in the 85th percentile of 336 allergy & immunology providers in Texas.

See all allergy & immunology providers in Texas

Medicare billing

Part B allowed, 2024
$4,292,806
Medicare patients
152
Services billed
69,070

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
HizentraImmun Glob G(Igg)/Pro/Iga 0-5022$82,520
Trelegy ElliptaFluticasone/Umeclidin/Vilanter22$19,118
Breo ElliptaFluticasone/Vilanterol13$7,448
AirsupraAlbuterol Sulfate/Budesonide14$7,037
AlvescoCiclesonide13$5,155
SymbicortBudesonide/Formoterol Fumarate13$4,364
Epinephrine14$2,309
Albuterol Sulfate HfaAlbuterol Sulfate43$1,641
Montelukast Sodium100$1,133
Ventolin HfaAlbuterol Sulfate13$925
Azelastine Hcl13$436
Doxycycline Hyclate15$398
Famotidine25$390
Fluticasone Propionate24$301
Azithromycin35$274

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
CSL BehringHizentra$187$82,52022 claims
GSKTrelegy Ellipta, Breo Ellipta$829$26,56535 claims
AstraZenecaAirsupra, Symbicort$1,029$11,40227 claims
Covis Pharma GmbHAlvesco$255$5,15513 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 336 allergy & immunology providers in Texas.

Other allergy & immunology in Plano

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →